GuiZhou SanLi Pharmaceutical Co., Ltd. Class A

GuiZhou SanLi Pharmaceutical Co., Ltd. Class A

SSSE:603439
10.00
CNY
-0.26
(-2.53%)
0.13EPS
100.57P/E
5.32BMarket Cap
Apr 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.24
5.52
3.41
1.54
1.75
1.96
2.39
1.61
2.28
2.92
3.97
5.24
4.05
4.06
Basic EPS, GAAP
0.15
0.6
0.5
0.22
0.24
0.3
0.36
0.24
0.37
0.49
0.71
0.67
0.11
0.13
Free Cash Flow per Basic Share
0.17
-0.53
-0.17
0.07
0.14
0.2
0.29
0.03
0.31
0.42
0.41
0.15
0.33
- -
Dividend per Share
0.01
0.05
0.01
0.19
0.12
0.19
- -
0.01
0.27
0.02
0.12
0.25
0.38
0.11
Book Value per Share
0.54
0.85
1.69
3.36
1.29
1.41
1.78
2.41
2.51
3.02
3.59
3.73
3.54
3.76
Tangible Book Value per Share
0.54
0.78
1.62
3.29
1.27
1.39
1.75
2.38
2.46
2.36
1.66
1.85
2
2.24
Basic Weighted Avg Shares
128
48
105
335
365
368
370
391
412
411
412
409
420
403
Sales/Revenue/Turnover
159
267
359
515
638
722
884
630
939
1,201
1,635
2,144
1,703
1,637
Operating Margin (%)
12.81
12.22
14.18
13.6
13.76
13.77
17.51
17.14
17.36
18.65
17.27
16.24
11.67
14.56
Depreciation Expense
2
2
2
7
7
8
8
8
11
16
37
76
74
- -
Net Income, GAAP
19
29
53
75
88
110
133
94
152
201
293
274
46
53
Effective Tax Rate (%)
14.53
14.68
14.13
14.2
15.29
15.11
14.59
14.51
15.88
13.76
11.72
13.9
28.94
33.75
Profit Margin (%)
12.16
10.86
14.65
14.55
13.73
15.29
15.06
14.91
16.22
16.76
17.9
12.78
2.72
3.23
Working Capital
45
55
95
304
346
348
486
656
739
623
654
564
492
587
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
254
210
150
150
Total Equity
69
109
217
431
473
518
651
982
1,032
1,238
1,709
1,595
1,512
1,585
Return on Invested Capital (%)
- -
20.04
22.12
17.17
16.04
16.81
22.32
10.4
12.43
14.41
15.83
12.43
2.03
2.43
Return on Capital (%)
- -
23.01
27.52
23.14
19.39
22.34
22.79
10.46
13.5
16.08
15.87
12.58
2.34
2.82
Return on Common Equity (%)
- -
32.58
32.33
23.14
19.39
22.29
22.77
11.51
15.13
17.73
21.61
18.28
3.11
3.53

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
558
487
518
LT Borrowings
150
150
150
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
409
409
404
Market Capitalization
4,482
5,157
5,323

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,499
1,265
1,423
Cash, Cash Equivalents & STI
376
312
348
Accounts Receivable, Net
684
526
675
Inventories
207
228
173
Total Current Liabilities
954
738
836
Payables & Accruals
- -
- -
- -
ST Debt
558
487
518
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.6%
10.25%
-5.17%
Free Cash Flow
100.56%
221.99%
124.23%
Net Income, GAAP
12.67%
10.04%
-83.12%
Sales/Revenue/Turnover
19.78%
24.72%
-20.59%
Total Cash Common Dividend
- -
928.26%
55.17%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
422
498
527
697
2,144
2025
409
293
- -
664
1,703
2026
382
178
413
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.15
0.19
0.2
0.67
2025
0.1
0.1
- -
-0.09
0.11
2026
0.11
-0.02
0.13
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.21
0.01
0.01
0.25
2025
0.01
0.36
- -
0.02
0.38
2026
0.01
0.07
0.01
- -
- -

Company Description

CEO
Qianfan Zhang
Full Time Employees
1,887
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Xiayun Industrial Park Anshun GZ China 561000
IPO Date
Apr 28, 2020
Business
GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) is a China-based pharmaceutical company engaged in the research, development, production and sale of chemical drugs, biological products and medical devices. The company offers a range of core products including anti-infective drugs such as Sanli Su (clindamycin phosphate glucose injection), Sanli Kang (ornidazole sodium chloride injection) and azithromycin series; cardiovascular drugs like metoprolol tartrate injection; sterile powder injections including omeprazole sodium, pantoprazole sodium and ceftazidime; and other offerings such as ambroxol hydrochloride oral solution, medical devices and disinfectants. It operates primarily in the domestic Chinese market with manufacturing facilities in Guizhou province and distributes through hospitals, pharmacies and wholesalers. Founded in 2001 and headquartered in Guiyang, Guizhou, the company focuses on sterile preparations and has expanded its portfolio through consistent R&D investments. In recent developments, GuiZhou SanLi Pharmaceutical completed a major production base expansion in 2024 to boost capacity for high-end injections, received CFDA approval for new formulations of its flagship anti-infective products in early 2025, and formed strategic partnerships with regional distributors to enhance market penetration amid China's healthcare reforms.